Bison Botanics

In September 2026, Bison Botanics concentrated 45.27% of sales in Flower with month-over-month growth of 3.48% despite a year-over-year decline of 2.17%, while Vapor Pens accounted for 32.56% share with year-over-year growth of 17.26% and a modest 0.56% month-over-month lift. Pre-Roll held 15.52% share with an 11.73% month-over-month increase but a 33.86% year-over-year contraction, and Beverage fell to 3.52% share with declines of 43.51% month-over-month and 66.17% year-over-year. Smaller lines compressed sharply: Tincture & Sublingual dropped 51.24% month-over-month and 55.86% year-over-year, and Topical fell 67.94% month-over-month and 79.28% year-over-year. The pattern indicates a pivot toward inhalables stabilizing near-term mix (Flower and Vapor Pens combining for 77.83% share) while non-inhalables retreat, enabling volume resilience even as overall brand sales fell 12.05% year over year and average price rose 9.79%.

These shifts imply Bison Botanics is consolidating around its core inhalable base to defend velocity while ceding breadth in ancillary formats, which can support price realization but raises exposure to category cyclicality. With Flower anchoring the mix yet carrying a year-over-year dip of 2.17% and Vapor Pens expanding 17.26% year-over-year, the brand’s short-term growth vector hinges on sustaining Vapor Pen gains as Pre-Roll volatility persists (+11.73% month-over-month versus −33.86% year-over-year). Given the Flower rank of 86 in New York and a 9.79% average price increase alongside a 12.05% brand sales decline year over year, the positioning skews toward maintaining share via depth in two inhalable categories rather than width across declining wellness and ingestible segments.